Skip to content
← All treatment topics

TREATMENT READING

Childhood Melanoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Melanoma Treatment.

Sources: Melanoma Treatment

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Childhood Melanoma

Source: Childhood Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network - European Registry) has published recommendations for the diagnosis and treatment of children and adolescents with cutaneous melanoma. Some of these recommendations have been incorporated and summarized in the sections below.[1] A Children's Oncology Group–led panel of experts from different specialties have also developed recommendations for the diagnostic evaluation and surgical management of cutaneous melanomas, atypical Spitz tumors, and non-Spitz melanocytic tumors.[2]

Sources: 1 · 2

Treatment options for childhood melanoma include the following:

Surgery and, in certain cases, sentinel lymph node biopsy and lymph node dissection.

Sources: Surgery

Immune checkpoint inhibitors or BRAF/MEK inhibitors.

Sources: Immune checkpoint inhibitors or BRAF/MEK inhibitors

Health professional · Treatment of Childhood Melanoma

Surgery

Source: Childhood Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Surgery is the treatment of choice for patients with localized melanoma. Current guidelines recommend margins of resection as follows:

0.5 cm for melanoma in situ.

1 cm for melanoma thickness of less than 1 mm.

1 cm to 2 cm for melanoma thickness of 1.01 mm to 2 mm.

2 cm for tumor thickness of greater than 2 mm.

Sentinel lymph node biopsy should be considered in patients with thin lesions (≤1 mm) and ulceration, mitotic rate greater than 1/mm2, young age, and lesions larger than 1 mm with or without adverse features. Younger patients have a higher incidence of sentinel lymph node positivity, and this feature may adversely affect clinical outcomes.[3,4]

Sources: 3 · 4

If the sentinel lymph node is positive, the option to undergo a complete lymph node dissection should be discussed. One adult trial included 1,934 patients with a positive sentinel node, identified by either immunohistochemistry or polymerase chain reaction. The patients were randomly assigned to undergo either complete lymph node dissection or observation. The 3-year melanoma-specific survival rate was similar in both groups (86%), whereas the disease-free survival (DFS) rate was slightly higher in the dissection group (68% vs. 63%; P = .05). This advantage in DFS was related to a decrease in the rate of nodal recurrences because there was no difference in the distant metastases–free survival rates. It remains unknown how these results will affect the future surgical management of children and adolescents with melanoma.[5]

Sources: 5

Health professional · Treatment of Childhood Melanoma

Immune Checkpoint Inhibitors or BRAF/MEK Inhibitors

Source: Childhood Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Targeted therapies and immunotherapy that have been effective in adults with melanoma should be pursued in pediatric patients with conventional melanoma and metastatic, recurrent, or progressive disease.

Evidence (targeted therapy and immunotherapy):

A phase I trial of ipilimumab in children and adolescents, at a dose of 5 mg/kg or 10 mg/kg every 3 weeks for four cycles, enrolled 12 patients with melanoma.[6]

Sources: 6

A phase I trial of ipilimumab in children and adolescents, at a dose of 5 mg/kg or 10 mg/kg every 3 weeks for four cycles, enrolled 12 patients with melanoma.[6]

One patient had prolonged stable disease.

This treatment demonstrated a similar toxicity profile as that seen in adults.

A phase II study of ipilimumab for adolescents with melanoma failed to achieve accrual goals and was closed. However, there was reported activity in patients with melanoma who were aged 12 to 17 years, with a similar safety profile as that seen in adults.[7][Level of evidence B4]

Sources: 7 · Level of evidence B4

A phase II study of ipilimumab for adolescents with melanoma failed to achieve accrual goals and was closed. However, there was reported activity in patients with melanoma who were aged 12 to 17 years, with a similar safety profile as that seen in adults.[7][Level of evidence B4]

At 1 year, three of four patients who received 3 mg/kg and five of eight patients who received 10 mg/kg were alive.

Two patients who received 10 mg/kg had partial responses, and one patient who received 3 mg/kg had stable disease.

In adults with completely resected stage III cutaneous melanoma, prolonged DFS and overall survival have been seen with ipilimumab given at a dose of 10 mg/kg every 3 weeks for four doses, followed by one dose every 3 months for up to 3 years. This regimen caused little impairment in health-related quality of life.

In a phase I/II trial of nivolumab for children and young adults with relapsed or refractory solid tumors or lymphoma, patients were treated with a dose of 3 mg/kg every 14 days.[8]

Sources: 8

In a phase I/II trial of nivolumab for children and young adults with relapsed or refractory solid tumors or lymphoma, patients were treated with a dose of 3 mg/kg every 14 days.[8]

The one patient with melanoma did not respond to therapy.

An open-label, single-arm, phase I/II trial of pembrolizumab for pediatric patients with advanced melanoma or programmed death-ligand 1 (PD-L1)–positive, advanced, relapsed, or refractory solid tumors or lymphoma reported the following:[9]

Sources: 9

An open-label, single-arm, phase I/II trial of pembrolizumab for pediatric patients with advanced melanoma or programmed death-ligand 1 (PD-L1)–positive, advanced, relapsed, or refractory solid tumors or lymphoma reported the following:[9]

Eight patients with melanoma were enrolled, and no responses were observed in these patients.

Five of these patients were PD-L1 negative.

The Children's Oncology Group conducted a phase I/II trial of ipilimumab and nivolumab in 55 children and young adults with refractory or recurrent solid tumors.[10]

Sources: 10

The Children's Oncology Group conducted a phase I/II trial of ipilimumab and nivolumab in 55 children and young adults with refractory or recurrent solid tumors.[10]

The study identified a recommended phase II dose of 3 mg/kg for nivolumab and 1 mg/kg for ipilimumab.

No patients with melanoma were enrolled in the trial. However, partial responses were seen in one patient with rhabdomyosarcoma and one patient with Ewing sarcoma.

A retrospective review identified 99 patients with melanoma (aged 18 years or younger) who were treated with systemic therapy at 15 Italian academic centers. Eighty-one patients received anti–PD-1 therapy. The median age was 14 years (range, 2–18 years), and 37 patients were aged 12 years or younger. Thirty-eight patients received anti–PD-1 therapy in the adjuvant setting.[11]

Sources: 11

A retrospective review identified 99 patients with melanoma (aged 18 years or younger) who were treated with systemic therapy at 15 Italian academic centers. Eighty-one patients received anti–PD-1 therapy. The median age was 14 years (range, 2–18 years), and 37 patients were aged 12 years or younger. Thirty-eight patients received anti–PD-1 therapy in the adjuvant setting.[11]

Of the patients who received adjuvant anti–PD-1 therapy, the 3-year progression-free survival rate was 70.6%, and the overall survival (OS) rate was 81.1%.

Of the 56 patients who received systemic therapy for advanced disease, 43 received first-line anti–PD-1–based therapy, while 12 patients received a second line, and 5 patients received a third line. Among patients who received first-line therapy with anti–PD-1 monotherapy, the objective response rate was 25%, and the 3-year OS rate was 34%.

Toxicities were consistent with previous studies that included adult patients with melanoma.

Dabrafenib and trametinib have been studied in two trials for pediatric patients with BRAF V600-altered low-grade gliomas. The U.S. Food and Drug Administration (FDA) approved this combination for this indication.[12,13] The FDA has also approved this combination for the treatment of patients with melanoma.

Sources: 12 · 13

No trials have been conducted specifically for the treatment of pediatric patients with melanoma. However, the FDA has approved the following immune and targeted therapies for pediatric and adolescent patients with melanoma based on studies of adult populations with or without pediatric participants:

Based on the positive results of two randomized clinical trials, the FDA approved adjuvant pembrolizumab for the treatment of patients aged 12 years and older with resected stage IIb, IIc, and III melanoma.[14,15]

Sources: 14 · 15

Based on the positive results of two randomized clinical trials, the FDA approved adjuvant nivolumab for the treatment of patients aged 12 years and older with resected stage IIb to IV melanoma.[16,17]

Sources: 16 · 17

Based on the positive results of one adult randomized clinical trial, the FDA approved nivolumab and ipilimumab for the treatment of children aged 12 years and older with unresectable or metastatic melanoma.[18]

Sources: 18

Based on the positive results of one randomized clinical trial, the FDA approved nivolumab with relatlimab for the treatment of children aged 12 years and older with unresectable or metastatic melanoma.[19]

Sources: 19

Although there have not been any prospective clinical trials using BRAF/MEK inhibitors in children and adolescents with melanoma, two adult studies have shown that the adjuvant combination of dabrafenib and trametinib results in a significantly lower risk of recurrence in patients with surgically resected stage III melanoma and in patients with previously untreated BRAF V600-altered metastatic melanoma.[20,21] The FDA granted accelerated approval to this drug combination for the treatment of patients with unresectable or metastatic melanoma who have BRAF V600E or V600K variants and for the adjuvant treatment of patients with melanoma who have BRAF V600E or V600K variants.

Sources: 20 · 21

For more information, see Melanoma Treatment.

Sources: Melanoma Treatment

Health professional

Treatment Options Under Clinical Evaluation for Childhood Melanoma

Source: Childhood Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 3, 2025. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

NCT02332668 (A Study of Pembrolizumab [MK-3475] in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma [MK-3475-051/KEYNOTE-051]): This is a two-part study of pembrolizumab in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumor or lymphoma. Part 1 will find the maximum tolerated dose/maximum administered dose, confirm the dose, and find the recommended phase II dose for pembrolizumab therapy. Part 2 will further evaluate the safety and efficacy of the phase II dose recommended for pediatric patients.

Sources: NCT02332668

For patients · Stages of Melanoma

Sometimes childhood melanoma recurs (comes back) after treatment.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

The cancer may come back in the skin, lymph nodes, or in other parts of the body.

For patients

Treatment Option Overview

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

There are different types of treatment for children with melanoma.

Children with melanoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.

Three types of standard treatment are used:

Three types of standard treatment are used:

Surgery

Immunotherapy

Targeted therapy

New types of treatment are being tested in clinical trials.

Treatment for childhood melanoma may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for children with melanoma.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.

Sources: standard · clinical trials · research study

Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.

For patients · Treatment Option Overview

Children with melanoma should have their treatment planned by a team of doctors who are experts in treating childhood cancer.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health professionals who are experts in treating children with cancer and who specialize in certain areas of medicine. This may include the following specialists and others:

Sources: pediatric oncologist · cancer · pediatric · medicine · specialists

Pediatrician.

Sources: Pediatrician

Dermatologist.

Sources: Dermatologist

Pediatric surgeon.

Sources: Pediatric surgeon

Pathologist.

Sources: Pathologist

Social worker.

Sources: Social worker

Rehabilitation specialist.

Sources: Rehabilitation specialist

Psychologist.

Sources: Psychologist

Child-life specialist.

Sources: Child-life specialist

For patients · Treatment Option Overview

Three types of standard treatment are used:

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

For patients · Treatment Option Overview / Three types of standard treatment are used:

Surgery

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Surgery to remove the tumor is used to treat childhood melanoma. A wide local excision is used to remove the melanoma and some of the normal tissue around it. Skin grafting (taking skin from another part of the body to replace the skin that is removed) may be done to cover the wound caused by surgery. Nearby lymph nodes with cancer may also be removed.

Sources: Surgery · tumor · melanoma · wide local excision · tissue · Skin grafting · wound · lymph nodes

For patients · Treatment Option Overview / Three types of standard treatment are used:

Immunotherapy

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. This type of cancer treatment is also called biotherapy or biologic therapy.

Sources: Immunotherapy · immune system

Immune checkpoint inhibitor therapy: There are different types of immune checkpoint inhibitor therapy:

Sources: Immune checkpoint inhibitor · therapy

Immune checkpoint inhibitor therapy: There are different types of immune checkpoint inhibitor therapy:

PD-1 inhibitor: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. When PD-1 attaches to another protein called PDL-1 on a tumor cell, it stops the T cell from killing the tumor cell. PD-1 inhibitors attach to PDL-1 and allow the T cells to kill tumor cells. Pembrolizumab and nivolumab are used to treat melanoma that has spread to lymph nodes and are being studied to treat recurrent melanoma.

Sources: PD-1 · protein · T cells · immune responses · cell · Pembrolizumab · nivolumab · recurrent

CTLA-4 inhibitor: CTLA-4 is a protein on the surface of T cells that helps keep the body’s immune responses in check. When CTLA-4 attaches to another protein called B7 on a cancer cell, it stops the T cell from killing the cancer cell. CTLA-4 inhibitors attach to CTLA-4 and allow the T cells to kill cancer cells. Ipilimumab is used to treat melanoma that has spread to lymph nodes or to other parts of the body and is being studied to treat recurrent melanoma.

Sources: CTLA-4 · Ipilimumab

For patients · Treatment Option Overview / Three types of standard treatment are used:

Targeted therapy

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to attack cancer cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. The following type of targeted therapy is being used or studied in the treatment of melanoma:

Sources: Targeted therapy · drugs · chemotherapy · radiation therapy

Signal transduction inhibitor therapy: Signal transduction inhibitors block signals that are passed from one molecule to another inside a cell. Blocking these signals may kill cancer cells. They are used to treat some patients with advanced melanoma or tumors that cannot be removed by surgery. Signal transduction inhibitors include the following:

Sources: Signal transduction inhibitor · signals · molecule · advanced

Signal transduction inhibitor therapy: Signal transduction inhibitors block signals that are passed from one molecule to another inside a cell. Blocking these signals may kill cancer cells. They are used to treat some patients with advanced melanoma or tumors that cannot be removed by surgery. Signal transduction inhibitors include the following:

BRAF inhibitors (dabrafenib, vemurafenib , or encorafenib) that block the activity of proteins made by mutant BRAF genes.

Sources: BRAF inhibitors · dabrafenib · vemurafenib · encorafenib · mutant · BRAF genes

MEK inhibitors (trametinib or binimetinib) that block proteins called MEK1 and MEK2 which affect the growth and survival of cancer cells.

Sources: MEK inhibitors · trametinib · binimetinib

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: clinical trials · NCI website

For patients · Treatment Option Overview

Treatment for childhood melanoma may cause side effects.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Childhood Melanoma

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of newly diagnosed melanoma that has not spread to lymph nodes or other parts of the body includes the following:

Sources: diagnosed · melanoma · lymph nodes

Surgery to remove the tumor and some healthy tissue around it.

Sources: Surgery · tumor · tissue

Treatment of newly diagnosed melanoma that has spread to nearby lymph nodes includes the following:

Surgery to remove the tumor and the lymph nodes with cancer.

Sources: cancer

Immunotherapy with immune checkpoint inhibitors (pembrolizumab, ipilimumab, or nivolumab).

Sources: Immunotherapy · immune checkpoint inhibitors · pembrolizumab · ipilimumab · nivolumab

Targeted therapy with BRAF inhibitors (vemurafenib, dabrafenib, or encorafenib) alone or with MEK inhibitors (trametinib or binimetinib).

Sources: Targeted therapy · BRAF inhibitors · vemurafenib · dabrafenib · encorafenib · MEK inhibitors · trametinib · binimetinib

Treatment of newly diagnosed melanoma that has spread to other parts of the body may include the following:

Immunotherapy (ipilimumab).

A clinical trial of an oral targeted therapy drug (dabrafenib) in children and adolescents.

Sources: clinical trial · oral · drug · adolescents

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Childhood Melanoma

Source: Childhood Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: October 18, 2021. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of recurrent melanoma in children may include the following:

Sources: recurrent · melanoma

A clinical trial that checks a sample of the patient's tumor for certain gene changes. The type of targeted therapy that will be given to the patient depends on the type of gene change.

Sources: clinical trial · tumor · gene · targeted therapy

A clinical trial of immunotherapy with immune checkpoint inhibitors (pembrolizumab, nivolumab, or ipilimumab) in children and adolescents.

Sources: immunotherapy · immune checkpoint inhibitors · pembrolizumab · nivolumab · ipilimumab · adolescents

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668 · RECRUITING · phase1, phase2

Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor

ClinicalTrials.gov record

Disease and treatment settings

Childhood Melanoma

Disease and treatment setting

Melanoma in children and adolescents

KEYTRUDA QLEX: melanoma (adjuvant) after prior therapy

Disease and treatment setting

KEYTRUDA QLEX is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with Stage IIB, IIC, or III melanoma following complete resection.

KEYTRUDA: melanoma (adjuvant) after prior therapy

Disease and treatment setting

for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.

OPDIVO QVANTIG: melanoma (adjuvant)

Disease and treatment setting

1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC,...

OPDIVO QVANTIG: unresectable metastatic melanoma

Disease and treatment setting

1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma.

OPDIVO QVANTIG: unresectable metastatic melanoma after prior therapy

Disease and treatment setting

OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and...

OPDIVO: melanoma (adjuvant)

Disease and treatment setting

• for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

OPDIVO: unresectable metastatic melanoma

Disease and treatment setting

1.1 Unresectable or Metastatic Melanoma OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.

OPDUALAG: unresectable metastatic melanoma

Disease and treatment setting

1 INDICATIONS AND USAGE OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

recurrent Childhood Melanoma

Disease and treatment setting

Treatment of Recurrent Childhood Melanoma

YERVOY: unresectable metastatic melanoma

Disease and treatment setting

1.1 Unresectable or Metastatic Melanoma YERVOY, as a single agent or in combination with nivolumab, is indicated for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.

Drug labels

OPDUALAG

Label date 2026-06-08

OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody,...

DailyMed label